FY2024 EPS Forecast for Hims & Hers Health Raised by Analyst

Hims & Hers Health, Inc. (NYSE:HIMS) – Seaport Res Ptn upped their FY2024 EPS estimates for shares of Hims & Hers Health in a research note issued to investors on Monday, November 4th. Seaport Res Ptn analyst A. Kessler now expects that the company will post earnings per share of $0.25 for the year, up from their previous estimate of $0.23. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.22 per share. Seaport Res Ptn also issued estimates for Hims & Hers Health’s FY2025 earnings at $0.51 EPS.

Other analysts have also recently issued reports about the company. Needham & Company LLC assumed coverage on Hims & Hers Health in a report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price target on the stock. Canaccord Genuity Group lifted their price objective on Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday. TD Cowen boosted their target price on shares of Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, July 11th. Truist Financial increased their price target on Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, July 18th. Finally, Imperial Capital downgraded shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Eight investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $21.00.

Hims & Hers Health Stock Performance

Shares of NYSE:HIMS opened at $23.62 on Thursday. The company has a market capitalization of $5.07 billion, a PE ratio of 54.80 and a beta of 1.06. Hims & Hers Health has a 52-week low of $6.58 and a 52-week high of $25.74. The company has a fifty day moving average of $18.40 and a 200-day moving average of $18.29.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.26. The business had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a return on equity of 11.67% and a net margin of 8.19%. Hims & Hers Health’s revenue was up 77.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.04) earnings per share.

Institutional Investors Weigh In On Hims & Hers Health

Large investors have recently added to or reduced their stakes in the company. Quantbot Technologies LP grew its position in Hims & Hers Health by 3,444.9% during the 1st quarter. Quantbot Technologies LP now owns 214,677 shares of the company’s stock worth $3,321,000 after acquiring an additional 208,621 shares during the last quarter. IvyRock Asset Management HK Ltd bought a new position in shares of Hims & Hers Health during the first quarter valued at approximately $433,000. Swiss National Bank raised its stake in Hims & Hers Health by 0.7% during the first quarter. Swiss National Bank now owns 281,500 shares of the company’s stock valued at $4,355,000 after buying an additional 2,000 shares during the last quarter. Sei Investments Co. boosted its stake in Hims & Hers Health by 206.9% in the 1st quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock worth $869,000 after purchasing an additional 37,890 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new stake in Hims & Hers Health during the 1st quarter valued at about $228,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Insider Activity

In other Hims & Hers Health news, Director Christiane Pendarvis sold 7,000 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $15.15, for a total transaction of $106,050.00. Following the sale, the director now owns 23,917 shares in the company, valued at $362,342.55. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Hims & Hers Health news, Director Christiane Pendarvis sold 7,000 shares of the firm’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $15.15, for a total value of $106,050.00. Following the completion of the transaction, the director now directly owns 23,917 shares of the company’s stock, valued at $362,342.55. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $20.88, for a total value of $3,943,981.44. Following the transaction, the chief executive officer now owns 67,015 shares of the company’s stock, valued at approximately $1,399,273.20. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 854,547 shares of company stock valued at $15,987,230 in the last 90 days. Insiders own 17.71% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.